Propanc Biopharma IncOTC Pink - Current Information:PPCB
- LAST PRICE0.0011
- TODAY'S CHANGE (%)0.0001 (10.0000%)
- Bid / Lots0.0011/ 16,363
- Ask / Lots0.0012/ 4,450
- Open / Previous Close0.0011 / 0.0010
- Day Range
- 52 Week Range
- Volume1,210,030
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | PPCB |
|---|---|---|
| 09:32 ET | 45000 | 0.0011 |
| 09:41 ET | 1300 | 0.0011 |
| 09:56 ET | 300000 | 0.0011 |
| 09:59 ET | 200000 | 0.0011 |
| 10:10 ET | 663700 | 0.0011 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Propanc Biopharma Inc | 52.1K | 0.0x | --- |
Petlife Pharmaceuticals Inc | 19.7K | 0.0x | --- |
Nxgen Brands Inc | 405.6K | 0.0x | --- |
Sunset Island Group Inc | 10.0 | 0.0x | --- |
Calithera Biosciences Inc | 122.1K | 0.0x | --- |
Earth Life Sciences Inc | 100.0K | -0.2x | --- |
Company Information
Propanc Biopharma, Inc. is an Australia-based clinical-stage biopharmaceutical company. The Company is focused on the development of cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancers. The Company has developed a rational, composite formulation of anti-cancer compounds, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its lead product candidate, PRP, is a variation upon its formulation and involves pro-enzymes, the inactive precursors of enzymes. PRP is a long-term therapy based on a pancreatic proenzyme formulation to prevent tumor recurrence and metastasis. PRP is a patented, formulation consisting of two proenzymes mixed in a synergetic ratio. PRP is in the preclinical phase of development.
Contact Information
- Headquarters
- 302/6 Butler Street, CamberwellMELBOURNE, VIC, Australia 3124
- Phone
- ---
- Fax
- ---
Executives
- Chief Executive Officer, Chief Financial Officer, Treasurer, Director
- James Nathanielsz
- Director
- Julian Kenyon
- Director
- Josef Zelinger
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $52.1K |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 52.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.82 |
EPS | $-0.72 |
Book Value | $-0.52 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
